Greater Cannabis Company, INC

The Greater Cannabis Company, Inc. announced a corporate name change to Trafalgar International, Inc., a 1-for-5 reverse stock split, and the appointment of three new directors and executive officers.

The Greater Cannabis Company, Inc. announces a change in control and the cancellation of $80,000 in debt through separate agreements.

The Greater Cannabis Company Inc. has granted its CEO, Aitan Zacharin, 51% voting control through new Series B Convertible Preferred Stock in exchange for waiving $20,000 in compensation.

The Greater Cannabis Company Inc. announced a one-day delay in its 1-for-1,500 reverse stock split due to an administrative oversight.

The Greater Cannabis Company Inc. announced a 1-for-1,500 reverse stock split, effective October 15, 2025, significantly reducing its outstanding shares.

The Greater Cannabis Company issued 100,000,000 restricted shares to its CEO, Aitan Zacharin, to cover $10,000 in deferred compensation.

The Greater Cannabis Company, Inc. filed its Q1 2026 10-Q, reporting a net loss of $33,376 and minimal cash, while detailing its strategic shift towards cannabinoid therapeutics and ongoing clinical trial preparations.

The Greater Cannabis Company reported a significant increase in net loss for the nine months ended September 30, 2025, alongside a reverse stock split and a new preferred stock issuance granting its CEO voting control.

The Greater Cannabis Company reported a significantly increased net loss and substantial dilution for Q2 2025, raising substantial doubt about its ability to continue as a going concern.

The Greater Cannabis Company, Inc. restated its Q1 2025 financial results to include significant note default penalties and interest, exacerbating its net loss and highlighting ongoing liquidity challenges.

The Greater Cannabis Company reported no revenue and an increased net loss for the quarter ended March 31, 2025, while continuing to focus on cannabinoid therapeutic development.

The Greater Cannabis Company reported no revenue and a net loss for the third quarter of 2024, while continuing to focus on the development of cannabinoid therapeutics.

The Greater Cannabis Company reported a significant net loss and cash depletion for 2025, raising substantial doubt about its ability to continue operations while awaiting critical API for its Phase II clinical trial.

The Greater Cannabis Company files an amendment to its 2024 annual report to include the 2023 auditor report and additional details on its licensing agreement with Shaare Zedek Scientific Ltd.

The Greater Cannabis Company reports $0 revenue for 2024 and expresses substantial doubt about its ability to continue as a going concern.

The Greater Cannabis Company reported no revenue and a net loss of $188,402 for the year ended December 31, 2023, while highlighting ongoing concerns about its ability to continue as a going concern.

Sapir LLC, managed by Aitan Zacharin, acquired 100 million shares of Greater Cannabis Company, Inc. at a price of $0.001 per share.

The Greater Cannabis Company is set to implement a one-for-1,500 reverse stock split and create a new class of Series B Convertible Preferred Stock, granting voting control to the CEO.

Trafalgar Asset Management, LLC, controlled by Porfirio Sanchez Talavera, has acquired a controlling interest in Greater Cannabis Company, Inc., leading to significant management changes.